KemPharm Inc (NASDAQ:KMPH) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.
- Updated: October 11, 2016
Zacks Investment Research has downgraded KemPharm Inc (NASDAQ:KMPH) to Hold in a report released on 10/12/2016.
On Tuesday August 16, 2016, Zacks Investment Research released a statement for KemPharm Inc (NASDAQ:KMPH) bumped up the target price from $0.00 to $4.75 that suggested a downside of -0.08%.
Boasting a price of $4.79, KemPharm Inc (NASDAQ:KMPH) traded 8.86% higher on the day. With the last stock price close down -35.88% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. KemPharm Inc has recorded a 50-day average of $4.63 and a two hundred day average of $7.47. Volume of trade was up over the average, with 325,950 shares of KMPH changing hands over the typical 70,255
With a total market value of $0, KemPharm Inc has with a one year low of $3.52 and a one year high of $21.30 .
A total of 4 equity analysts have released a ratings update on KMPH. Two equity analysts rating the company a strong buy, two equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $32.75.
Brief Synopsis About KemPharm Inc (NASDAQ:KMPH)
KemPharm, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company's product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP). The Company is developing KP201/APAP as an immediate release (IR), a product candidate for the short-term, or no longer than 14 days for the management of acute pain. The Company has designed KP201/APAP with abuse-deterrent properties to address the epidemic of opioid abuse in the United States. The Company also focuses on developing the pipeline of additional prodrug product candidates that targets pain and attention deficit hyperactivity disorder (ADHD). The Company's products include KP201/IR (APAP-free), KP511/ER, KP415, KP606/IR and KP746.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.